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HIV-1 non-macrophage-tropic R5 envelope
glycoproteins are not more tropic for entry into
primary CD4+ T-cells than envelopes highly
adapted for macrophages
Thomas Musich1, Olivia O’Connell1, Maria Paz Gonzalez-Perez1, Cynthia A Derdeyn2, Paul J Peters1 and Paul R Clapham1,3*
Abstract
Background: Non-mac-tropic HIV-1 R5 viruses are predominantly transmitted and persist in immune tissue even in
AIDS patients who carry highly mac-tropic variants in the brain. Non-mac-tropic R5 envelopes (Envs) require high
CD4 levels for infection contrasting with highly mac-tropic Envs, which interact more efficiently with CD4 and
mediate infection of macrophages that express low CD4. Non-mac-tropic R5 Envs predominantly target T-cells
during transmission and in immune tissue where they must outcompete mac-tropic variants. Here, we investigated
whether Env+ pseudoviruses bearing transmitted/founder (T/F), early and late disease non-mac-tropic R5 envelopes
mediated more efficient infection of CD4+ T-cells compared to those with highly mac-tropic Envs.
Results: Highly mac-tropic Envs mediated highest infectivity for primary T-cells, Jurkat/CCR5 cells, myeloid dendritic
cells, macrophages, and HeLa TZM-bl cells, although this was most dramatic on macrophages. Infection of primary
T-cells mediated by all Envs was low. However, infection of T-cells was greatly enhanced by increasing virus
attachment with DEAE dextran and spinoculation, which enhanced the three Env+ virus groups to similar extents.
Dendritic cell capture of viruses and trans-infection also greatly enhanced infection of primary T-cells. In
trans-infection assays, non-mac-tropic R5 Envs were preferentially enhanced and those from late disease mediated
levels of T-cell infection that were equivalent to those mediated by mac-tropic Envs.
Conclusions: Our results demonstrate that T/F, early or late disease non-mac-tropic R5 Envs do not preferentially
mediate infection of primary CD4+ T-cells compared to highly mac-tropic Envs from brain tissue. We conclude that
non-macrophage-tropism of HIV-1 R5 Envs in vitro is determined predominantly by a reduced capacity to target
myeloid cells via low CD4 rather than a specific adaptation for T-cells entry that precludes macrophage infection.
Keywords: HIV-1, Tropism, Macrophage-tropism, Non-macrophage-tropism, Dendritic cells, Trans-infection,
Envelope, T-cells, Macrophages, Functionality
Background
HIV-1 infects cells expressing CD4 and either CCR5 or
CXCR4 [1]. HIV-1 isolates that use CCR5 were believed to
infect both T-cells and macrophages and were classified as
macrophage-tropic (M-tropic), while isolates using CXCR4
preferentially infected T-cells and were described as
T-tropic [1]. However, the term ‘M-tropic’ to describe all
CCR5-using variants is no longer valid since it has become
clear that they vary extensively in their ability to infect mac-
rophages [2-10]. Macrophage-tropic (mac-tropic) R5 strains
can still replicate despite low levels of cell surface CD4 on
macrophages for infection, while non-macrophage-tropic
(non-mac-tropic) R5 viruses require high amounts of CD4,
presumably limiting them to CD4+ T-cells that express
significantly more CD4 compared to macrophages [2,3,11].
The majority of transmitted or founder viruses described
are non-mac-tropic R5 viruses [12-17] and viruses with this
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phenotype remain predominant in immune tissue [2,3]
even at late stages of disease when mac-tropic variants can
be increasingly detected in blood [18-20] and brain tissue
[2,3,5,11,21-25]. These observations emphasize that CD4+
T-cells are the major cellular targets for HIV during trans-
mission and throughout disease in immune tissue.
Determinants that modulate R5 macrophage infection
have been mapped to residues within or proximal to the
CD4 binding site on gp120 of the HIV-1 envelope glyco-
protein (Env) [11,26,27] as well as in the variable V1
[28], V2 and [29] V3 loops [26] at the apex of the trimer
[30]. These data are consistent with mac-tropic R5 Envs
carrying a higher affinity for CD4, which includes in-
creased initial binding of CD4 by the outer domain on
gp120 but also more efficient triggering of the conform-
ational changes that shift the V1V2 loops and open the
trimer to enable CD4 to recruit determinants on the
V1V2 stem to form the bridging sheet [31]. Our studies
with neutralizing mabs that target the V2 and V3 loops
support this interpretation and hint at structural changes
in highly mac-tropic R5 Envs at the trimer apex that fa-
cilitate CD4 induced opening and formation of the
bridging sheet and coreceptor binding site [31].
The presence of highly mac-tropic Envs in brain tissue
represents an adaptation for replication in macrophages
and microglia, which form the main HIV reservoir there.
However, the factors in immune tissue that preferentially
favor high CD4-requiring, non-macrophage-tropic R5 vi-
ruses rather than variants that interact efficiently with CD4
are less clear. We previously hypothesized [8,31] that non-
macrophage-tropic Envs in immune tissue evolve Env tri-
mers that are tightly closed with poor access to the CD4
binding site to protect against neutralizing antibodies.
These Envs will require high concentrations of CD4 to trig-
ger opening and assembly of the coreceptor binding site.
In contrast, mac-tropic Envs in the immunoprivileged en-
vironment of the brain are only exposed to low antibody
concentrations [32-34] and can evolve to open more read-
ily in response to low CD4 levels. Surprisingly, we failed to
show a significant difference in the sensitivity of non-
mac-tropic Env+ pseudovirions to heterologous neutraliz-
ing antibodies in HIV-1+ human sera compared to those
carrying highly mac-tropic brain-derived Envs [31]. In
addition, the maintenance of the non-mac-tropic R5 Env
phenotype during transmission and in the acute phase
[12,14-17] when neutralizing antibodies (nabs) are usually
absent, suggest the presence of additional selective forces
that favor non-mac-tropic R5 viruses. An alternative hy-
pothesis is that non-mac-tropic R5 Envs have evolved to
mediate maximal replication in T-cells (rather than macro-
phages) i.e. they are T-cell tropic, even though they confer
a lower Env:CD4 affinity compared to mac-tropic R5 Envs.
Here, we investigated whether non-mac-tropic R5 Envs
mediate an enhanced tropism for T-cells. Our data show
that non-mac-tropic R5 Envs either from early or late dis-
ease do not mediate more efficient infection of CD4+ T-
cells compared to mac-tropic Envs, even though they are
likely to predominantly target T-cells and dominate over
more mac-tropic variants in immune tissue in vivo. These
results point to additional unknown selective pressures that
enable non-mac-tropic R5 viruses to out-compete mac-
tropic variants in immune tissue throughout disease.
Results
Infection of macrophages and HeLa TZM-bl cells
We first compared Env+GFP-reporter pseudovirion infec-
tion of primary macrophages with infectivity for TZM-bl
cells (Figure 1). Mac-tropic Envs mediated high levels of
infectivity for macrophages as expected with infectivity ti-
ters that were several orders of magnitude higher than for
non-mac-tropic late disease Envs (Figure 1A). Of the T/F/
acute R5 Envs, only R66M conferred a moderately high
level of macrophage infection albeit still at a level lower
than the highly mac-tropic R5 Envs.
HeLa TZM-bl cells express high levels of CD4 and
CCR5 and are highly permissive to a broad range of HIV
[2,3]. All Env+ pseudoviruses mediated high levels of infec-
tion of HeLa TZM-bl cells. However, the T/F/acute Envs
and some of the late stage non-mac-tropic Envs mediated
significantly lower levels of TZM-bl infection compared to
mac-tropic Envs (Figure 1B). These Envs may be less func-
tional (i.e. they need more Env to achieve the same level of
infectivity as other Envs) or they may assemble less effi-
ciently onto pseudovirions. Either situation could result in
underestimating their ability to mediate macrophage infec-
tion. To correct for this, we related Env+ pseudovirus in-
fectivity for macrophages to TZM-bl infectivity by plotting
macrophage infectivity titers as a percent of TZM-bl titers
(Figure 1C). This approach suggests that T/F/acute Envs
are not as tightly non-mac-tropic as late disease immune
tissue Envs, yet are still significantly less mac-tropic com-
pared to the highly mac-tropic Envs.
Infection of CD4+ T-cells
Non-mac-tropic R5 variants are predominant in immune
tissue, where CD4+ T-cells expressing high levels of
CD4 are the major target cells [2,3,23]. We tested
whether the T/F, acute and late non-mac-tropic R5 Envs
have an increased ability to confer infection of CD4+
T-cells compared to highly mac-tropic R5 Envs. We first
evaluated infection for Jurkat/CCR5 cells (Figure 2A, left
panel and Additional file 1: Figure S3A). All Env +
pseudoviruses mediated infection, although levels were
low, varying from 0.062-2.65% of those recorded on
TZM-bl cells. The mac-tropic R5 Envs consistently
mediated significantly higher infection of Jurkat/CCR5
cells than both non-mac-tropic T/F/acute (p = 0.0036)
and late disease (p = 0.016) Envs (Figure 2A).
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We next tested infection on primary CD4+ T-cells.
PBMCs obtained from at least two separate donors were
stimulated with PHA and IL-2 before enriching for CD4
+ T-cells via negative selection (Stemcell Tech. Inc.) and
tested for infection using the GFP reporter pseudovir-
ions. Both mac-tropic and non-mac-tropic R5 Envs
conferred infection of CD4+ T-cells. However, infection
for all Env+ pseudoviruses was surprisingly very low
(Figure 2B, left panel and and Additional file 1: Figure
S3B) with infectivity titers ranging from 0 – 0.33% of
those recorded for HeLa TZM-bl cells. Neither do CD4
or CCR5 levels explain the low overall infection levels
observed for Jurkat/CCR5 and primary CD4+ T-cells.
Jurkat/CCR5 cells express low to high levels of CD4 and
high CCR5, while primary CD4+ cells express high CD4
and variable CCR5 (data not shown and [35,36]).
Similar to Jurkat/R5 T-cell infectivity, primary T-cell
infectivity for mac-tropic R5 Envs was significantly higher
compared to non-mac-tropic, late disease R5 Envs
(p = 0.0078) and compared to T/F/acute Envs (p = 0.0009).
As described above, T/F/acute and some late disease
non-mac-tropic Envs mediated lower levels of infection
for TZM-bl cells (compared to highly mac-tropic Envs),
suggesting that they are less functional or carry lower
levels of Env in pseudovirion preparations. To correct
for different Env+ pseudovirus infectivities (measured on
TZM-bl cells), we plotted T-cell infectivity as a percent-
age of the infectivity titers measured on TZM-bl cells.
For both Jurkat/CCR5 and primary T-cells, values were
similar for late disease mac-tropic and non-mac-tropic
Envs (Figure 2A, B right panels and Additional file 1:
Figure S3A-B), although T/F/acute Envs were higher for
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Figure 1 Env+ pseudovirion infection of HeLa TZM-bl and macrophages. (A) Macrophage-tropic R5 Envs mediate 100-1000-fold higher
infection of macrophages compared to T/F/acute and late disease non-mac-tropic R5 Envs. (B) Several late disease non-mac-tropic Envs and most
T/F/acute Envs mediated lower infection of HeLa TZM-bl cells compared to macrophage tropic Envs. (C) Plotting macrophage infectivity titers as
a percent of TZM-bl titers suggests that T/F/acute Envs are not as non-mac-tropic as late disease non-mac-tropic Envs. Significant differences were
evaluated using Mann Whitney or Wilcoxon matched pair tests as described in Materials and Methods. Pseudoviruses carrying clade B Envs are
represented by black symbols, those with clade C Envs by light gray symbols, clade A by hatched symbols and CRF A/C by dark gray. Median
values are marked.
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Jurkat/CCR5 cells and this just reached significance
(p = 0.0158). CD4+ T-cell infectivity plotted as a percent
of TZM-bl infectivity, was not significantly different
among the 3 Env groups (Figure 2B, right panel). Taken
together, none of this data convincingly supports a
higher T-cell entry tropism for non-mac-tropic R5 Envs.
Infection of MDDCs
We tested whether myeloid dendritic cells (mDCs) were
susceptible to infection by mac-tropic or non-mac-tropic
R5 Env+ pseudovirions. Myeloid DCs are derived from
the same cell lineage as monocytes and macrophages
and like these cell types, express low levels of CD4 [35].
Myeloid DCs express SAMHD1 [37,38] and sometimes
APOBEC3G [39-41], restriction factors with the poten-
tial to restrict HIV replication. The low levels of CD4
and the presence of restriction factors has led to a con-
sensus view that these cells are relatively insensitive to
HIV-1 infection in vivo [42].
We prepared mDCs from blood monocytes as
monocyte-derived dendritic cells (MDDCs) using stand-
ard (IL-4, GM-CSF) differentiation protocols [43,44]
followed by maturation by LPS (0.1 μ/ml) and negative
selection via magnetic beads (StemCell Tech. Inc.). We
tested their sensitivity to infection by the panel of GFP-
reporter Env+ pseudovirions (Figure 2C left panel and
Additional file 1: Figure S3C). MDDCs were poorly sus-
ceptible to Env + pseudoviruses (Figure 2C, left panel),
with highly mac-tropic Envs mediating detectable infec-
tion more consistently than non-mac-tropic T/F/acute
Envs. MDDC infectivity plotted as a percent of TZM-bl
infectivity, was variable but not significantly different
among the 3 Env groups (Figure 2C, right panel).
DEAE dextran and spinoculation rescue infection of CD4+
T-cells but not MDDCs
T/F and non-mac-tropic Envs bind CD4 less efficiently
than mac-tropic Envs [2,3,11,26] and it is possible that
such Envs mediate less efficient binding of virions to
CD4+ T-cells. We reasoned that this could be revealed
by preferential enhancement of T-cell infection by
non-mac-tropic Envs (compared to mac-tropic Envs)
following DEAE dextran and spinoculation mediated at-
tachment of virions. In parallel with the direct infectivity
assays shown in Figure 2, we tested if infection of CD4+
T-cells could be facilitated by increasing attachment of
virus particles using DEAE dextran (DD) and spinocula-
tion and compared with MDDC infection. Our data
showed a significant enhancement of infection for CD4+
T-cells by all Env+ pseudovirions by an average of
>10-fold, with the three Env+ virus groups enhanced to
similar extents (Figure 3A, C). Importantly, this data is
consistent with non-mac-tropic Envs (including T/F
Envs) binding to T-cells with similar efficiencies as mac-
tropic variants. In contrast to T-cells, DD and spinocula-
tion had little effect on the low levels of infection
detected for MDDCs (Figure 3B).
Mac-tropic R5 Envs mediated the highest infection
levels for T-cells in the presence of DD and spinocula-
tion (Figure 3A), with infection significantly higher than
T/F/acute Envs (p = 0.0025) and late disease non-mac-
m
ac
-tr
op
ic
no
n-
m
ac
-tr
op
ic
T/
F/
ac
ut
e
100
101
102
103
104
105
106
m
ac
-tr
op
ic
no
n-
m
ac
-tr
op
ic
T/
F/
ac
ut
e
0.001
0.01
0.1
1
10
100
In
fe
ct
iv
ity
 %
 o
f 
T
Z
M
-b
l
A. Jurkat/CCR5 
F
F
U
/m
l 
p=0.016* p=0.0036 ** 
p=0.016* 
m
ac
-tr
op
ic
no
n-
m
ac
-tr
op
ic
T/
F/
ac
ut
e
0.0001
0.001
0.01
0.1
1
10
100
m
ac
-tr
op
ic
no
n-
m
ac
-tr
op
ic
T/
F/
ac
ut
e
100
101
102
103
104
105
106
B. T-cells 
In
fe
ct
iv
ity
 %
 o
f T
Z
M
-b
l
F
F
U
/m
l 
p=0.0009 *** 
p=0.0078** 
m
ac
-tr
op
ic
no
n-
m
ac
-tr
op
ic
T/
F/
ac
ut
e
100
101
102
103
104
105
106
m
ac
-tr
op
ic
no
n-
m
ac
-tr
op
ic
T/
F/
ac
ut
e
0.001
0.01
0.1
1
10
100
In
fe
ct
iv
ity
 %
 o
f T
Z
M
-b
l
F
F
U
/m
l 
C. MDDCs 
p=0.0033** 
Figure 2 Infection of Jurkat/CCR5, primary CD4+ T-cells and
primary MDDCs by pseudovirions carrying mac-tropic and
non-mac-tropic R5 envelopes. Env+ GFP-reporter pseudovirus
infection of Jurkat/CCR5 (A), primary CD4+ T-cells (B) and LPS matured
MDDCs (C). Left panels shows FFU measured as GFP+ cells per ml of
input virus. Right panels show infectivity as a percent of TZM-bl
infectivity. Significant differences were evaluated using Mann Whitney
or Wilcoxon matched pair tests as described in Methods. Only the p
values that were significant are shown. Symbol colour designations are
the same as described in Figure 1. Please also refer to Additional file 1:
Figure S3, where FFU/ml for each Env+ pseudovirus is presented in bar
graphs with standard deviation bars shown, while the column scatter
plot of infectivity as a percent of TZM-bl infectivity is presented with
each point labeled for Env used. Median values are marked.
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tropic (p = 0.016) R5 Envs. Plotting infectivity titers as a
percent of HeLa TZM-bl indicated that DD and spino-
culation facilitated T-cell infection by mac-tropic and
non-mac-tropic Envs from early and late in infection
with similar efficiencies (Figure 3C and Additional file 1:
Figure S4).
MDDC-mediated trans-infection of T-cells
DCs capture HIV-1 particles and present them to CD4+
T-cells via synapses. This process bypasses the require-
ment for cell-free virions to attach directly to T-cells.
However, presented virions still need to bind CD4 and
CCR5, which are concentrated on the T-cell side of the
synapse, for fusion and entry to be triggered. This trans-
infection process greatly increases the efficiency of CD4
+ T-cell infection [45-47]. We evaluated whether non-
mac-tropic Envs that target T-cells in vivo had evolved
more efficient entry via trans-infection compared to
mac-tropic Envs. Both immature and mature DCs are
capable of eliciting trans-infection of CD4+ T-cells
[45,47]. However, mature DCs are the most efficient for
this process [48-50]. We therefore tested whether LPS-
matured MDDCs first treated with Env+ pseudovirions
could confer efficient infection of autologous CD4+ T-
cells. In the direct infectivity assays for MDDCs and
CD4+ T-cells described above, target cells had been
treated with Env+ pseudoviruses for three hours before
adding growth medium without washing. For the trans-
infection assays, we limited MDDC exposure to virus to
1 hour, before washing and co-culturing with autologous
PHA, IL-2 stimulated CD4+ T-cells. In parallel, MDDCs
and CD4+ T-cells were treated separately with Env+
pseudovirions for one hour before washing and incubat-
ing. Direct infection of MDDCs and CD4+ T-cells using
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Figure 3 DEAE dextran and spinoculation enhance infection for CD4+ T-cells but not for MDDCs. Infection in the presence and absence
of DEAE dextran and spinoculation on CD4+ T-cells (A) and MDDCs (B). DEAE dextran and spinoculation enhance non-mac-tropic Envs and
mac-tropic Envs to similar extents (C). Significant differences were evaluated using Mann Whitney or Wilcoxon matched pair tests as described in
Materials and Methods. Figure 3 experiments were done in conjunction with the direct infections shown in Figure 2. Figure 3 data for infection
without DEAE dextran and spinoculation is therefore the same as that shown in Figure 2. Only the p values relevant for DEAE dextran and
spinoculation that show significance are shown. Symbol colour designations are the same as described in Figure 1. Please also refer to Additional
file 1: Figure S4, where FFU/ml for each Env+ pseudovirus is presented in a bar graph with standard deviation bars shown, while the column
scatter plot of infectivity as a percent of TZM-bl infectivity is presented with each point labeled for Env used. Median values are marked.
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this approach was very low and variable (Figure 4A).
Trans-infection via MDDCs resulted in substantially
higher levels (>10-fold) of CD4+ T-cell infection com-
pared to direct infection of T-cells or MDDCs alone
(Figure 4A).
Trans-infection of CD4+ T-cells by late stage non-mac-
tropic Envs was not significantly different compared to
mac-tropic Envs (Figure 4A), contrasting with significant
differences detected for TZM-bl, macrophage, Jurkat/CD4
and primary T-cell infection shown in Figures 1, 2 and 3.
This result suggests that trans-infection preferentially en-
hances late disease non-mac-tropic Envs over mac-tropic
Envs. However, while trans-infection greatly enhanced T-
cell infection for T/F/acute Envs, infectivity was still signifi-
cantly lower compared to the highly mac-tropic R5 Envs
(p = 0.04).
We next plotted MDDC/T-cell infectivities as a percent
of those measured on the highly susceptible HeLa TZM-bl
cells to correct for possible differences in the efficiency of
pseudotype production from 293 T cells. Figure 4B sug-
gests that late stage non-mac-tropic R5 Env+ pseudoviruses
are enhanced to a significantly greater extent than mac-
tropic pseudovirions, although this was not significant.
These experiments suggest that trans-infection via
MDDCs preferentially enhances infection mediated by
non-mac-tropic R5 Envs from late disease over highly
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Figure 4 MDDC mediated trans-infection of CD4+ T-cells by Env+ pseudovirions. (A) Trans-infection of CD4+ T-cells following virion capture by
MDDCs is substantially more efficient than cell free infection of T-cells or MDDCs alone. T/F/acute and late disease non-mac- and mac-tropic R5 Env+
pseudovirions are all enhanced. Note that for late disease non-mac-tropic and mac-tropic R5 Envs, trans-infectivity titers are not significantly different.
Infectivities are shown as the number of FFU/ml (GFP+ cells per ml) of input virus. (B) Infectivity as a percent of infection for TZM-bl cells suggests that
trans-infection preferentially enhances non-mac-tropic R5 Env+ pseudovirions, although differences are not significant. Symbol colour designations are
the same as described in Figure 1. Please also refer to Additional file 1: Figure S5, where FFU/ml for each Env+ pseudovirus is presented in a bar graph
with standard deviation bars shown, while the column scatter plot of infectivity as a percent of TZM-bl infectivity is presented with each point labeled for
Env used. Median values are marked.
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mac-tropic Envs. However, trans-infection did not confer
higher T-cell infection for late disease non-mac-tropic
R5 Envs and did not fully rescue T/F/acute stage Envs.
Nevertheless, these observations emphasize the role cell:
cell transfer of virus must play during transmission and
viral replication in immune tissue particularly for non-
mac-tropic Envs.
Discussion
We investigated T-cell tropism of non-mac-tropic R5
Envs that require high levels of CD4 for infection includ-
ing several T/F and acute stage Envs and compared to
highly mac-tropic variants mostly derived from brain tis-
sue. Viruses carrying non-mac-tropic R5 Envs predomin-
ate in immune tissue where they presumably carry a
selective advantage over, and outcompete more mac-
tropic R5 variants that evolve. We wanted to evaluate
whether their predominance was due to the evolution of
an enhanced ability of the envelope glycoproteins to me-
diate infection of CD4+ T-cells. However, none of the
data presented indicates that non-mac-tropic Envs con-
sistently mediate more efficient infection of CD4+ T-
cells compared to mac-tropic Envs.
A limitation of our study is that we focused on Env
and viral entry rather than full length viral clones and
full replication. Viral entry includes attachment, receptor
interactions, fusion etc., and is likely to be an important
determinant of tropism in vivo, with adaptation for CD4,
CCR5 binding and escape from neutralizing antibodies
potential responses to selective pressures in vivo. Never-
theless, it is possible that non-mac-tropic Envs mediate
enhanced replication in the context of multiple replica-
tion cycles that include Env expression and assembly.
We took two approaches to compare the infectivity of
mac-tropic and non-mac-tropic R5 Env+ pseudoviruses.
First, we titrated different Env+ pseudoviruses on each
cell type and compared their infectivity. This approach
showed that pseudoviruses carrying mac-tropic Envs
mediated significantly higher levels of infection for mac-
rophages, Jurkat/CCR5 and primary T-cells compared to
non-mac-tropic Envs. Only when T-cells were trans-
infected via MDDCs, did late disease non-mac-tropic
Envs mediate similar levels of infection compared to
mac-tropic Envs suggesting that this route of infection
may preferentially support viruses carrying non-mac-
tropic Envs.
One concern is that different Env+ pseudovirus prepa-
rations generated in 293 T cells may vary in the amount
of infectious virus produced, which is influenced by vari-
ation in transfection efficiency, levels of Env assembled
and differences in the functionality of each Env. So, in a
second approach, we standardized our Env+ pseudovirus
infectivity data by plotting infectivity titers as a percent
of that measured on highly permissive HeLa TZM-bl cell
line as we previously reported [2,3]. All Env+ pseudo-
viruses mediated respectable infectivity titers on HeLa
TZM-bl cells (Figure 1B). However, the lower titers for
several late disease non-mac-tropic Envs and particularly
for T/F/acute Envs could in part explain their lower
levels of infectivity for the other cell types types tested
here. Plotting infectivity as a percent of TZM-bl infectiv-
ity corrects for differences in overall pseudovirus infect-
ivity and showed that non-mac-tropic Envs mediated
similar levels of infectivity for Jurkat/CCR5 and primary
T-cells compared to mac-tropic Envs. However, this ap-
proach still did not provide evidence to suggest that
non-mac-tropic Envs were more T-cell tropic compared
to mac-tropic Envs.
Using HeLa TZM-bl titers to normalize Env+ pseudo-
virus infectivity is a useful approach. However, it does not
discern whether decreased titers for non-mac-tropic Env+
pseudoviuses could be due to Envs being less functional or
expressed less efficiently. We speculate that non-mac-
tropic viruses replicating in immune tissue may evolve
Envs that are tightly closed to protect against neutralizing
antibodies. Such Envs may be less functional compared to
mac-tropic Envs from the brain i.e. they need more Env to
achieve the same level of infectivity as mac-tropic Envs.
Envs that are inherently less functional will result in less in-
fectious virions in vivo as well as in vitro. We tried to
evaluate whether different Env+ pseudovirus preparations
varied in the amount of gp120 present or whether some
Envs were less functional. To evaluate gp120 concentra-
tions in Env+ pseudovirus preparations, we used a com-
mercial ELISA assay to measure gp120 levels present in
Env+ pseudovirus preparations as an overall measure of
Env expression. However, this approach was only partially
successful due to variation in the sensitivity in detection of
gp120s from different clade B and particularly non-clade B
Envs. However, we were able to investigate gp120 levels in
pseudotype preparations carrying clade B Envs from sev-
eral of the late disease subjects. This additional data
provides evidence that gp120 levels in pseudoviruses of
non-mac-tropic Envs are slightly lower for some subjects,
but also suggests that several non-mac-tropic Envs are less
functional than mac-tropic Envs from the same subject
(Additional Data text and Additional file 1: Figure S6).
These data suggest that at least some non-mac-tropic Envs
are less functional than highly mac-tropic Envs, but not
more tropic for T-cell entry.
Env+ pseudovirus infection of primary CD4+ T-cells
with cell-free virus was surprisingly low for all Envs.
However T-cell infection was greatly increased by facili-
tating attachment and perhaps cell activation using
DEAE dextran and spinoculation [51]. This observation
is consistent with a defect in virion binding, which is
overcome either by DEAE dextran and spinoculation or
via MDDC capture of viral particles and trans-infection
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of CD4+ T-cells. We also used enhancement of infection
by DEAE dextran and spinoculation to explore whether
the different virus groups bound to CD4+ T-cells differ-
ently. Mac-tropic Envs bind CD4 much more efficiently
compared to T/F and other non-mac-tropic R5 viruses
and might be expected to preferentially bind to CD4+ T-
cells. Alternatively, it is possible that non-mac-tropic vi-
ruses (that replicate in T-cells in immune tissue) may be
able to bind to T-cells effectively even without a strong
Env: CD4 interaction. We couldn’t use direct virus bind-
ing assays to test this as it is not possible to distinguish
between infectious and non-infectious virions (with the
latter being the most abundant). However, we reasoned
that differences in binding of infectious virions to CD4+
T-cells could be revealed by enhancing attachment with
DEAE dextran and spinoculation. For example, DEAE
dextran and spinoculation might be expected to prefer-
entially aid attachment to CD4+ T-cells by T/F and
non-mac-tropic Env+ viruses, which bind CD4 with low
efficiency compared to mac-tropic Envs. Importantly,
our data indicates that this is not the case and that non-
mac-tropic Envs (including T/F Envs) bind to T-cells
with similar efficiency as mac-tropic variants.
Trans-infection following capture of virions by
MDDCs helped all Env+ viruses overcome the deficit of
cell-free virus binding to T-cells. After attachment to
MDDCs, viruses are then targeted to DC:T-cell synapses
where CD4 and CCR5 (highly concentrated on the T-cell
side [49]) trigger fusion and entry. This environment
preferentially enhanced infection of late disease non-
mac-tropic Env+ viruses, resulting in levels of T-cell
infection that were not significantly different compared
to mac-tropic Env+ viruses. The mechanistic basis be-
hind preferential enhancement of non-mac-tropic Env+
viruses is unclear. However, it is likely that the concen-
tration of CD4 on the T-cell side of the synapse plays a
major role, enabling non-mac-tropic Env+ virions to
bind several CD4 molecules to increase avidity of attach-
ment. This process may help such Envs overcome a low
affinity for CD4 to trigger fusion. It is also important to
point out that we did not study the transfer of HIV par-
ticles from an infected T-cell to uninfected T-cells via
virological synapses i.e. cis-infection [52]. Nevertheless,
our observations support an important role for trans-
infection and synapse dependent entry in the replication
of HIV in immune tissue and for late disease non-mac-
tropic viruses in particular.
T/F viruses and those replicating in the acute stage of
infection are believed to predominantly target T-cells
[53-55]. Some studies support an enhanced fitness for T/F
viruses [56,57], although others failed to confirm that T/F
Env genes mediated higher infection of T-cells [58,59].
Here, we studied a diverse panel of T/F and acute stage
Envs for T-cell infection. T/F/acute Envs generally yielded
pseudovirions with lower infectivity (compared to late dis-
ease Envs) for the different cell types tested. Several of the
T/F/acute Envs were from clade A and C, with one an A/C
recombinant. Env+ pseudoviruses were made using a clade
B env-minus pNL4.3 clone that provided all viral proteins
except Env to form virus particles. While all Envs yielded
Env+ pseudoviruses with respectable infectivity titers on
HeLa TZM-bl cells, we can’t rule out the possibility that
lower TZM-bl infectivity titers for some of the non-clade B
Envs was due to reduced Env assembly on to clade B viral
cores.
Our data do not support the evolution of Envs that
preferentially mediate T-cell entry over mac-tropic vari-
ants. The requirement of non-mac-tropic R5 Envs for
high CD4 levels to induce infection is likely to be a
major factor in limiting their replication to T-cells and
excluding them from cells expressing lower CD4 levels,
rather than an enhanced and Env-determined specific
tropism for T-cell entry that precludes macrophage in-
fection. While we believe that neutralizing antibodies
may be a major selective force in immune tissue follow-
ing their generation, it remains unclear why the non-
mac-tropic phenotype is maintained during the acute
stage of replication before sero-conversion when HIV
specific antibodies are absent. An important conclusion
from our results is therefore that there must be a power-
ful unknown force during transmission, the acute phase
and in immune tissue throughout disease, that selects
against envelopes that can mediate macrophage infection
so that variants with non-mac-tropic Envs are the fittest
and prevail.
Conclusions
We demonstrate that T/F, early or late disease non-mac-
tropic R5 Envs do not confer an enhanced T-cell entry
tropism compared to mac-tropic Envs. We show that
virion capture by mDCs and subsequent trans-infection
of T-cells via synapses is important for optimal infection
by non-mac-tropic R5 Env+ viruses, enhancing infectiv-
ity to levels equivalent to mac-tropic viruses, but not
higher. We conclude that non-macrophage-tropism of
HIV-1 R5 Envs is determined in part by an adaptation to
an unknown environmental pressure that constrains
mac-tropic variants.
Methods
Envelope clones
We investigated 33 R5 envelopes previously character-
ized as highly mac-tropic or non-mac-tropic (Table 1)
[2,3,23,60]. Mac-tropic and non-mac-tropic R5 enve-
lopes from seven AIDS patients were included. We used
at least one highly mac-tropic and one non-mac-tropic
Env+ from each individual. For subject NA20, we inves-
tigated a second highly mac-tropic Env and for CA110,
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we included two highly mac-tropic R5 Envs, one from
brain and one from spleen alongside two non-mac-
tropic Envs from spleen. All these envelopes had previ-
ously been highly characterized and their genotypes and
phenotypes described [2,3,23,61]. We also tested mac-
tropic JR-FL and non-mac-tropic JR-CSF, which were
derived from the same individual and have been used ex-
tensively in HIV research [4].
For comparison with these late disease envelopes, we in-
cluded 13 envelopes that were derived from early in infec-
tion. Sexually transmitted viruses were reported to carry
fewer glycans [65-71] and shorter variable loops [72,73] that
may confer an enhanced fitness [56], although this is less
clear for clade B viruses [68,70,74,75]. These early viruses
predominantly target T-cells [53-55] and are thus the most
likely to be highly adapted for T-cells. We selected a diverse
range of envelopes from different clades to provide the best
chance of establishing whether we could detect any early
stage Envs that were more efficient than late disease mac-
tropic Envs for infection of CD4+ T-cells. We included
‘transmitter/founder’ (T/F) envs constructed from the con-
sensus sequences of early, replicating virus [60] as well as
some from the acute stage of replication. These included four
clade B ‘transmitter/founder’ (T/F) envelopes and 9 clade A,
AC and C envs derived from the acute stages of infection
[62,63,66,76]. All envs were expressed from Rev-Env expres-
sion vectors, which confer efficient Env expression and the
formation of Env+ pseudovirions. Most envs were expressed
from pcDNA3.1TOPO. Envs from subjects NA20, NA420,
P1114 and JR were expressed from pSVIIIenv. Both vectors
have been shown to support the production Env+ pseudovir-
ions with equivalent levels of infectivity (not shown).
Table 1 T/F, acute, late stage non-mac-tropic and late stage mac-tropic R5 Envs
Patient Clade Non-mac-tropic Mac-tropic Reference
Env Origin Full ID Env Origin Full ID
AIDS patients
NA20 B LN8 LN1 B59 FL2 [3]
B501 FL
NA420 B LN40 LN B33 FL [3]
JR B JR-CSF CSF3 JR-FL FL [4]
P1114 B 98-27 Plasma 98-15 Plasma [3]
P7766 B SP1 Spleen SP13-33-41 FL2 FL FL19-56-66 [23]
P10017 B SP2 Spleen SP10-9-65 FL1 FL FL9-1-2 [23]
P6568 B SP1 Spleen SP6-11-9 FL1 FL FL11-1-249 [23]
CA110 B SP2 Spleen SP53-23-131 OC1 OL4 OC58-11-57 [23]
SP3 SP4 Spleen Spleen SP53-6-122 SP52-16-50 SP1 Spleen SP52-13-34
T/F
3 T B 3 T Plasma p1054.TC4.1499 [60]
6 T B 6 T Plasma p63358.p3.4013 [60]
15 T B 15 T Plasma p700010040.C9.4520 [60]
19 T B 19 T Plasma pPRB958_06.TB1.4305 [60]
Acute Stage
R463F A1 R463F Plasma R463FPL16MAR07EnvE44 [62]
R880F A1 R880F Plasma R880FPL12JAN07EnvA6 [63]
Z185F C Z185F Blood Z185FPB24AUG02ENV3.1 [63,64]
Z205F C Z205F Blood Z205FPB27MAR03ENV1.1 [63,64]
R66M A/C R66M Plasma R66MPL7MAR06.3A9Env [63]
Z1792M C Z1792M Plasma Z1792MPL18DEC07.3G7Env2 [63]
Z201M C Z201M Plasma Z201MPL7FEB03ENV2.1 [13]
Z221M C Z221M Plasma Z221MPL7MAR03ENV2.1 [13]
Z153M C Z153M Plasma Z153MPL13MAR02ENV5.1 [13]
We selected pairs of highly mac-tropic and non-mac-tropic R5 Envs from 8 subtype B infected AIDS patients (including JR-FL and JR-CSF) for study. For subject
NA20, we included 2 highly mac-tropic Envs. For CA110, we included two highly mac-tropic Envs and two non-mac-tropic spleen Envs. Except for JR-FL and JR-
CSF, all Envs had been PCR amplified directly from patient tissues. We also included 13 diverse R5 Envs previously reported as T/F or isolated from the acute stage
of infection. In this group, we included Envs from different subtypes. 1. Lymph node; 2. Frontal lobe; 3. Cerebral spinal fluid; 4. Occipital lobe.
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Cell cultures
293 T cells were used to prepare Env-containing (Env+)
pseudovirions by transfection. Env+ pseudovirions were
first titrated on HeLa TZM-bl cells [77]. 293 T and HeLa
TZM-bl cells were cultured in Dulbecco modified Eagle
medium (DMEM) with 4% fetal bovine serum (FBS) and
gentamicin (10 μg/mL).
Jurkat E6-1 cells stably expressing CCR5 were ob-
tained from H. Gottlinger. CCR5 had previously been in-
troduced using pCXbst-CCR5 vector. These cells were
cultured in 10% FBS in RPMI with 5 μg/ml blasticidin.
Primary macrophages were prepared from elutriated
blood monocytes. Briefly, 0.5 ml of elutriated monocytes
(5x105/ml) was plated in each well of 48-well cell culture
dishes and cultured in 10% human AB+ plasma in
DMEM for 5 to 7 days before infection. Alternatively,
5x107 peripheral blood mononuclear cells (PBMC) from
a buffy coat (Research Blood Components LLC, Boston,
MA) were plated into 14-cm bacterial culture dishes for
3 h before extensively washing away non-adherent cells,
culturing overnight, and repeating the washes. The ad-
hered monocytes were then cultured for 5 to 7 days in
10% AB+ human plasma in DMEM before treatment
with EDTA and transfer to 48-well tissue culture dishes
the day prior to infection [2,3].
MDDCs were prepared from blood monocytes by ad-
herence using standard procedures [44]. They were cul-
tured in DMEM+ 10% fetal calf serum containing
100 ng/mL granulocyte-macrophage colony stimulating
factor (GM-CSF) and 40 ng/mL IL-4 (Peprotech Inc.)
for 5 days. MDDCs were then activated with LPS
(100 ng/ml) for 48 hours before infection [44]. The day
before infection, MDDCs were treated with EDTA for
7 minutes at 37°C, before gently scraping from the flask,
undergoing DC negative selection to remove any con-
taminating cells using EasySep (Stemcell Technologies)
and plating into 96 well plates for assays. Activated
MDDCs expressed CD11c and showed high expression
of CD83, markers for DCs and activated DCs respect-
ively (not shown).
Primary PBMCs were isolated from whole human
blood or buffy coats by Ficoll-Paque separation. Cells
were washed twice with sterile PBS and cultured in
RPMI medium with 10% fetal bovine serum (FBS), 5 μg/
ml phytohemagglutinin and after two days, with IL-2
(5 ng/mL, Roche Inc.). CD4+ T-cells were isolated from
stimulated PBMCs using negative selection for CD4+
T-cells (Stemcell Technologies).
Preparation of Env+ pseudoviruses
1.25 μg of Env+ plasmids carrying rev-env sequences
were co-transfected with 1.25 μg of pNL43 that carried a
premature stop codon in the envelope gene and
0.625 μg of pHIvec2-GFP plasmid [78] into 293T cells
using calcium phosphate (Profection mammalian trans-
fection kit, Promega Inc.) [2]. The cell supernatant was
changed 8-18 hrs post-transfection (4% FBS DMEM).
Pseudovirions were harvested 48 h post-transfection,
clarified by low-speed centrifugation, aliquoted into
0.5 ml portions, and snap-frozen in liquid nitrogen.
Infectivity assays
We used Env+ pseudovirions carrying a GFP reporter
gene to investigate infection of different cell types.
Following infection of cells, GFP is expressed from a
reporter gene so that only infected cells become GFP+
(Additional file 1: Figure S1A-D). This system allows
infected GFP+ cells to be observed using fluorescent
microscopy and this was particularly important in trans-
infection assays where infected T-cells can easily be dis-
tinguished from MDDCs. All Env+ pseudoviruses were
titrated on each cell type, with undiluted and tenfold di-
lutions of virus supernatant added. Infectivities were
expressed as FFU/ml with each GFP+, infected cell
representing an individual focus of infectivity. Infectivity
was also standardized to titers measured on HeLa TZM-
bl cells and plotted as infectivities as a percent of TZM-
bl infectivity. Infectivity titers were usually calculated
from wells containing 10-150 GFP+ cells per well. We
confirmed that estimates of infectivity for primary
T-cells (as percentages of HeLa TZM-bl FFUs) stayed
the same over a range of 2-fold dilutions of Env+ pseu-
doviruses where 10-150 FFUs were counted. In this ex-
periment, estimates of infectivity (as percent of TZM-bl
titers) varied by less than 1.5-fold across at least 4 two-
fold dilutions (Additional file 1: Figure S2). This ap-
proach allowed us to measure maximal infectivity for
each Env+ pseudovirus on specific cell targets as well as
relating infectivity to that measured on the highly per-
missive TZM-bl cell line. Infectivity data for the different
cell types was averaged from two independent experi-
ments. For primary cells, at least two independent exper-
iments were done on cells derived from different donors.
Infection details for specific cell types are described
below.
HeLa TZM-bl cells were plated at 0.5 ml per well
(5x105 cells/ml) in 48-well dishes the day prior to infec-
tion and infected with Env+ pseudovirions carrying a
GFP reporter gene. After 72 h, GFP+ FFU were quanti-
fied by microscopy [2].
Macrophages seeded in 48 well plates were pretreated
with 0.1 ml DEAE dextran (10 μg/ml) in DMEM
medium containing 10% human plasma for 30 min at
37°C before Env+ pseudoviruses carrying a GFP reporter
gene were added and spinoculating plates for 45 minutes
in a benchtop centrifuge [51]. Infected macrophages
were incubated for a further 3 h at 37°C before the
addition of 0.4 ml of DMEM (10% FBS) and incubating
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at 37°C for seven days. DEAE dextran and spinoculation
enhance virus infectivity by approximately 20-fold by in-
creasing attachment [51] and entry [79]. Infection follow-
ing this procedure does not bypass the requirement of
CD4 and CCR5 for infection, which remains sensitive to
entry inhibitors including maraviroc (not shown). Env+
pseudovirions are capable of only a single round of replica-
tion so that focus-forming units (FFU) were estimated 5-7
days post-infection by counting individual GFP+ cells by
fluorescent microscopy.
CD4+ T-cells, MDDCs and Jurkat clones were infected
with GFP reporter Env+ pseudovirus in 96-well plates
(1.3 × 105 cells/well). CD4+ T-cells and MDDCs were
infected in the presence and absence of DEAE dextran
and spinoculation as described above. 100 μL of viral su-
pernatants were added to wells, and infection quantified
2 days post infection by counting GFP+ cells using a
fluorescent microscope. Env+ pseudovirus infectivities
were plotted directly and also as a percent of infectivity
measured in HeLa TZM-bl cells.
Trans-infection assay
IL-4, GM-CSF and LPS (100 ng/ml) activated MDDCs
were treated with EDTA, scraped, enriched by negative se-
lection and aliquoted into 96-well V bottom plates (9 × 104
cells/well) the day before assay. 100 μL of Env+ pseudo-
virus supernatant was added, and cells incubated for 1 hr
at 37°C. Cells were then washed three times with PBS, and
co-cultured with autologous CD4+ T-cells prepared as de-
scribed above. Cells in each well were then transferred into
96-well flat bottom cell culture plates. Infectivity was quan-
tified 2 days post infection by counting GFP+ T-cells. GFP
+ T-cells were readily distinguished from MDDCs by their
small rounded morphology. In trans-infection experiments,
the vast majority of GFP+ cells were T-cells. CD4+ T-cells
and MDDCs were also infected individually in parallel with
the MDDC/T-cell cocultivations, before washing after
1 hour and incubating as described above.
ELISA measurements of gp120 and p24
The concentration of gp120 in Env+ pseudovirion prepa-
rations was measured using an HIV-1 gp120 antigen
capture assay (Advanced Bioscience Laboratories Inc.),
while p24 levels were measured using an HIV-1 p24
antigen capture assay (Advanced Bioscience Laboratories
Inc.). Assays were performed using unpurified 293T su-
pernatants containing pseudoviruses.
Statistics
Significant differences between values for different Env
groups were evaluated using Mann Whitney or Wilcoxon
matched pair tests using Prism 6 for Mac OS X. Wilcoxon
matched paired tests were used to compare Envs from late
disease where each pair of Envs was derived from an
individual subject. Mann Whitney tests were used to com-
pare unrelated T/F/acute Envs with late disease Envs. For
some subjects, more than one mac-tropic or non-mac-
tropic Env was derived from an individual. In this situation,
values were averaged so that only one value per Env group
per subject was analyzed.
Additional file
Additional file 1: Additional data and figures. Figure S1. Infection of
cells using a GFP reporter+ Env+ pseudovirus. (A) HeLa TZM-bl; (B)
primary CD4+ T-cells; (C) CD4+ T-cells infected following MDDC capture
of virions and trans-infection. Note a GFP+ T-cell adjacent to a clump of
MDDCs, which also contains additional GFP+ cells that are out of the
plane of focus; (D) infected MDDC; and (E) Low level infection of MDDCs
is inhibited by AZT. Note: please view electronic version of panels A-D.
Figure S2. Estimation of Env+ pseudovirus infectivity for CD4+ T-cells as
a percent of that measured on HeLa TZM-bl. Left panel; FFU counts from
infection of primary T-cells using 2-fold dilutions of Env+ pseudovirus
preparations. Right panel; Estimation of infectivity as a percent of TZM-bl
using FFU counts. Figure S3. Env+ pseudovirus infectivity for Jurkat/
CCR5 (A), primary T-cells (B) and MDDCs (C). For each cell type, infectivity
is plotted as FFU/ml of input virus with standard deviations shown (top
panels), Env+ pseudovirus infectivities as percentages of that recorded on
HeLa TZM-bl are also shown as labeled points in a column scatter plot
(bottom panels). Symbol colour designations are the same as described
in Figure 1. Figure S4. Env+ pseudovirus infectivity for CD4+ T-cells
following DEAE dextran and spinoculation. See Figure S3 for more details.
Figure S5. Env+ pseudovirus infectivity for CD4+ T-cells following MDDC
capture and trans-infection. See Figure S3 for more details. Figure S6. (A)
Gp120 and p24 concentrations in Env+ pseudovirus preparations of late
stage Envs of 6 individuals. (B) HeLa TZM-bl infectivity plotted as a
ratio with gp120 (left) or p24 (right) concentrations. TZM-bl/gp120 ratios
(shown in B, left lanel) indicate that non-mac-tropic Envs from 4 of 6
individuals are less functional compared to mac-tropic Envs (i.e. they
need more Env to achieve the same level of infectivity as their
mac-tropic counterparts).
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